This study correlates plasma levels of Zinc (Zn) and some pituitary and testicular hormones in 20 uremic men (aged 17-58 years) on a weekly peritoneal dialysis program. Patients were compared to 12 healthy male volunteers (aged 28-40 years). In uremic men, plasma androstenedione (A) was elevated, while testosterone (T), dihydrotestosterone (DHT), and Zn were low. On a group basis, plasma follicle stimulating hormone (FSH) and luteinizing hormone (LH) were normal while prolactin was increased. A negative correlation was observed between plasma A and LH levels, as well as between the AIT+ DHT ratio and plasma Zn concentrations.Our results suggest a diminished A-to-T conversion and point to the possible role of Zn in the enzyme activity of the 17 Phydroxysteroid dehydrogenase.
Plasma zinc (Zn), follicle stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), and androgens concentrations were determined in 15 male patients with chronic renal failure who were successful recipients of kidney transplant. After 25 +/- 8.5 months of the renal transplant, Zn levels were (88 +/- 4 g/dl) lower than in the control group (116 +/- 5 micrograms/dl). Normal concentrations for androstenedione (A) (0.63 +/- 0.05 ng/ml) and testosterone (T) (3.31 +/- 0.15 ng/ml) were found. Dihydrotestosterone (DHT) levels (0.38 +/- 0.01 ng/ml) were lower than normal (1.11 +/- 0.09 ng/ml), suggesting a blockade in the conversion of T to DHT. Eleven of the 15 patients showed higher PRL levels (9.5 +/- 0.8 ng/ml) in contrast with the normal group (3.6 +/- 0.3 ng/ml). Ten patients received orally 2-alpha-bromoergocriptine (BEC) 2.5 mg/day for ten days. Plasma PRL decreased to 2.6 +/- 1.0 ng/ml (p less than 0.001), but A and T levels did not significantly change; however, DHT increased from 0.38 +/- 0.02 ng/ml to 0.72 +/- 0.04 ng/ml (p less than 0.01). All patients showed an increase in both gonadotropins before BEC without significant changes after treatment. The high PRL levels may be responsible for the impaired conversion of T to DHT, possibly by interference with the enzyme 5 alpha-reductase.
The plasma levels of androstenedione (A), testosterone (T), dihydrotestosterone (DHT), follicle stimulating hormone (FSH), luteinizing hormone (LH), and prolactin (PRL) were studied in 15 men (aged 24-50 years) with chronic renal failure under periodic peritoneal dialysis, before and after 50 mg of elemental zinc (Zn) orally, twice a day for three weeks. Before treatment, they were divided into three groups: group I, plasma A above normal and PRL less than 100 ng/ml; group II, low or normal A levels with PRL less than 100 ng/ml; and group III, normal or high A levels with PRL greater than 100 ng/ml. After oral Zn, plasma FSH, LH, and PRL were unchanged in all groups; however, in groups I and II plasma A was within normal T and DHT rose significantly, the A/(T+DHT) ratio decreased to normal, and the T/DHT ratio rose above normal. In group III plasma androgens remained low and androgen ratios were unchanged. Oral Zn seems to improve the conversion of A to T and also uncovered the possibility that plasma PRL levels greater than 100 ng/ml might cause a blockade in the 5 alfa-reductase.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.